Skip to main content
. 2022 Oct 3;12:949261. doi: 10.3389/fonc.2022.949261

Figure 5.

Figure 5

Assessment of EV isolation procedure compatibility with functional assays. (A) Histograms representing FACS viability assays of MOLM-13 (I) and EL08-1D2 cells (II) after treatment with different EV isolation buffers for 48 h (n = 5), and representative images of EL08-1D2 cells after 48 h treatment with the different isolation buffers (III). (B) FACS analysis of latex beads loaded with CD63-eGFP expressing MOLM-13-derived EVs following different isolation methods (n = 4). (C, D) Internalization assay of MOLM-13-derived EV (GFP- EV) or CD63-eGFP expressing MOLM-13-derived EV (GFP+ EV) into target cells (EL08-1D2, n = 10 independent experiments; MSC, n = 4 different donors; HSPCs, n = 6 different donors) with or without additional heparin (hep) treatment. Quantification of GFP-positive cells (C) and corresponding confocal microscopy images (scale bar set to 20 µm) (D). *p<0.05, **p<0.01, ****p<0.0001.